Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03890120 · ClinicalTrials.gov registry record · Phase 3
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
NCT03890120 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 419 participants.
The verdict
NCT03890120, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Interventions
- DRUG Placebo
- DRUG Cilofexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2022-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03890120
The ClinicalTrials.gov registry entry for NCT03890120 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03890120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03890120 about?
NCT03890120 is a clinical study titled "Study of Cilofexor in Adults With Primary Sclerosing Cholangitis". The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
What is the current status of trial NCT03890120?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2019-03-27. Estimated completion is 2022-12-23.
What interventions are being tested in trial NCT03890120?
The interventions under investigation include: Placebo (DRUG), Cilofexor (DRUG).
Who is sponsoring clinical trial NCT03890120?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.